Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.
Sign Up to like & getrecommendations! Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.01.007
Abstract: Trials of anti-inflammatory therapies in non-relapsing progressive multiple sclerosis (MS) have been stubbornly negative except recently for an anti-CD20 therapy in primary progressive MS and a S1P modulator siponimod in secondary progressive MS. We argue… read more here.
Keywords: therapeutic lag; sclerosis; multiple sclerosis; length dependent ... See more keywords